{"groups":[{"description":"Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV on Days 1, 2, 3 for 6 cycles.","id":"FG000","title":"Fludarabine+Cyclophosphamide (FC)"},{"description":"Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/m² IV on Day 0; Cycles 2-6: 500 mg/m² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.","id":"FG001","title":"Fludarabine+Cyclophosphamide+Rituximab (FCR)"}],"periods":[{"milestones":[{"achievements":[{"comment":"Informed consent unavailable for 2 patients at time of analysis; intent-to-treat population was 407.","groupId":"FG000","numSubjects":"409"},{"comment":"Informed consent unavailable for 5 patients at time of analysis; intent-to-treat population was 403.","groupId":"FG001","numSubjects":"408"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"398"},{"groupId":"FG001","numSubjects":"402"}],"type":"Safety Population; Received Study Drug"},{"achievements":[{"comment":"Completed all 6 cycles of study medication.","groupId":"FG000","numSubjects":"267"},{"comment":"Completed all 6 cycles of study medication.","groupId":"FG001","numSubjects":"300"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"142"},{"groupId":"FG001","numSubjects":"108"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}